Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
OPTUS Pharmaceutical Co., Ltd. Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.	South Korea	131030
Opus Genetics, Inc. Developing gene therapies for inherited retinal diseases and other blinding conditions.	United States of America	IRD
ORAGENICS INC Biotech developing intranasal drugs for concussion and other brain disorders.	United States of America	OGEN
Oramed Pharmaceuticals Inc. Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.	Israel	ORMP
ORASURE TECHNOLOGIES INC Develops and distributes point-of-care diagnostic tests and sample collection devices.	United States of America	OSUR
Orexo Develops pharmaceuticals & digital health for opioid use disorder in the US market.	Sweden	ORX
ORGANIGRAM GLOBAL INC. Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.	United States of America	OGI
Organon & Co. A global healthcare company focused on women's health, biosimilars, and established brands worldwide.	United States of America	OGN
Oric Pharmaceuticals, Inc. Developing therapies to overcome resistance in lung and prostate cancer.	United States of America	ORIC
Orion Oyj Develops and manufactures human/vet pharma, APIs, and generics for global markets.	Finland	ORNAV